MA39770A - Protéines agonistes du récepteur trail monocaténaires - Google Patents

Protéines agonistes du récepteur trail monocaténaires

Info

Publication number
MA39770A
MA39770A MA039770A MA39770A MA39770A MA 39770 A MA39770 A MA 39770A MA 039770 A MA039770 A MA 039770A MA 39770 A MA39770 A MA 39770A MA 39770 A MA39770 A MA 39770A
Authority
MA
Morocco
Prior art keywords
receptor agonist
agonist proteins
trail
chain trail
trail receptor
Prior art date
Application number
MA039770A
Other languages
English (en)
Inventor
Fritz G Buchanan
Christian Gieffers
Oliver Hill
Susan E Lappe
Darren C Phillips
Meinolf Thiemann
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of MA39770A publication Critical patent/MA39770A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)

Abstract

La présente invention concerne des protéines agonistes du récepteur trail spécifique, des acides nucléiques codant pour ces dernières, et des méthodes de traitement d'un sujet ayant une maladie ou un trouble associé(e) au récepteur trail. Les protéines agonistes du récepteur trail de la présente invention comprennent trois domaines trail solubles et un fragment fc. Les protéines agonistes du récepteur trail sont sensiblement non agrégeantes et appropriées pour des applications thérapeutiques, diagnostiques et/ou de recherche.
MA039770A 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires MA39770A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
MA39770A true MA39770A (fr) 2015-10-29

Family

ID=53055121

Family Applications (2)

Application Number Title Priority Date Filing Date
MA039770A MA39770A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires
MA045069A MA45069A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA045069A MA45069A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires

Country Status (38)

Country Link
US (5) US9908927B2 (fr)
EP (2) EP3366699A1 (fr)
JP (2) JP6523331B2 (fr)
KR (2) KR20190135546A (fr)
CN (2) CN106459221B (fr)
AR (1) AR100168A1 (fr)
AU (3) AU2015249649B2 (fr)
BR (1) BR112016024515B1 (fr)
CA (2) CA2946402C (fr)
CL (1) CL2016002683A1 (fr)
CR (1) CR20160516A (fr)
CY (1) CY1120281T1 (fr)
DK (1) DK3134430T3 (fr)
DO (1) DOP2016000284A (fr)
EC (1) ECSP16089579A (fr)
ES (1) ES2672368T3 (fr)
HR (1) HRP20180950T1 (fr)
HU (1) HUE038914T2 (fr)
IL (2) IL248244B (fr)
LT (1) LT3134430T (fr)
MA (2) MA39770A (fr)
MX (2) MX2016013858A (fr)
MY (1) MY181986A (fr)
NO (1) NO2776305T3 (fr)
PE (1) PE20170299A1 (fr)
PH (2) PH12020500377A1 (fr)
PL (1) PL3134430T3 (fr)
PT (1) PT3134430T (fr)
RS (1) RS57153B1 (fr)
RU (1) RU2699285C2 (fr)
SG (3) SG10202111785VA (fr)
SI (1) SI3134430T1 (fr)
SM (1) SMT201800286T1 (fr)
TR (1) TR201806912T4 (fr)
TW (2) TWI747178B (fr)
UA (1) UA118286C2 (fr)
UY (1) UY36095A (fr)
WO (1) WO2015164588A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2754432T3 (es) * 2015-05-04 2020-04-17 Apogenix Ag Proteínas agonistas de receptor CD40 de cadena sencilla
CA3002741A1 (fr) * 2015-10-23 2017-04-27 Apogenix Ag Proteines agonistes du recepteur gitr a chaine unique
CA3002587A1 (fr) * 2015-10-23 2017-04-27 Apogenix Ag Proteines agonistes du recepteur light a chaine unique
EP3364995B1 (fr) 2015-10-23 2021-08-04 Apogenix AG Protéines agonistes du récepteur cd27 à chaîne unique
WO2017102010A1 (fr) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Nouvelles protéines de fusion à cytokine
CA3054286A1 (fr) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois Variants et proteines de fusion de l-asparaginase ayant une activite l-glutaminase reduite et une stabilite amelioree
AU2017234679A1 (en) * 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
EP3360898A1 (fr) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
JP7744621B2 (ja) * 2017-08-11 2025-09-26 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (fr) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer
EP4149964A2 (fr) 2020-05-15 2023-03-22 Apogenix AG Modulateurs immunitaires multi-spécifiques
AU2022281108A1 (en) 2021-05-28 2023-12-14 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (fr) 2021-11-16 2023-05-25 Apogenix Ag Modulateurs immunitaires multi-spécifiques

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (fr) 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (fr) 2000-07-21 2002-01-21 Robert Simoneau Puce c
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003091447A2 (fr) * 2002-04-26 2003-11-06 California Institute Of Technology Acides nucleiques d1-1, polypeptides et methodes associees
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CN101160323A (zh) * 2005-04-15 2008-04-09 拉帕波特家族医学科学研究所 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (fr) 2006-08-28 2008-03-05 Apogenix GmbH Protéines de fusion de la superfamille TNF
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
CA2726087A1 (fr) 2008-06-03 2009-12-10 Tariq Ghayur Immunoglobulines a deux domaines variables et leurs utilisations
ES2538122T3 (es) 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
WO2010033315A1 (fr) 2008-09-22 2010-03-25 Amgen Inc. Procédé de traitement
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
BR112012017164A2 (pt) 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
WO2011130324A1 (fr) * 2010-04-13 2011-10-20 Medimmune, Llc Échafaudages multimériques à base de domaine de fibronectine de type iii
EP2793947B1 (fr) * 2011-12-23 2021-02-03 Innate Pharma Conjugaison enzymatique de polypeptides
EP3409686B1 (fr) * 2012-07-18 2022-04-13 Apogenix AG Composition comprenant un mélange d'isoformes de cd95-fc

Also Published As

Publication number Publication date
US20150337027A1 (en) 2015-11-26
US9908927B2 (en) 2018-03-06
US20180222962A1 (en) 2018-08-09
PH12016502079A1 (en) 2016-12-19
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
TWI683825B (zh) 2020-02-01
SMT201800286T1 (it) 2018-07-17
BR112016024515A2 (pt) 2017-10-10
CA3184067A1 (fr) 2015-10-29
CN106459221A (zh) 2017-02-22
TR201806912T4 (tr) 2018-06-21
CR20160516A (es) 2017-05-10
EP3134430B1 (fr) 2018-03-21
IL248244A0 (en) 2016-11-30
SG10201806465TA (en) 2018-08-30
CY1120281T1 (el) 2019-07-10
KR20190135546A (ko) 2019-12-06
TWI747178B (zh) 2021-11-21
JP6714751B2 (ja) 2020-06-24
EP3366699A1 (fr) 2018-08-29
HRP20180950T1 (hr) 2018-08-10
CA2946402C (fr) 2023-02-28
SG10202111785VA (en) 2021-12-30
MX2016013858A (es) 2017-08-02
NO2776305T3 (fr) 2018-01-27
PH12020500377A1 (en) 2022-11-14
MA45069A (fr) 2019-04-03
LT3134430T (lt) 2018-05-10
SI3134430T1 (en) 2018-05-31
IL248244B (en) 2020-03-31
AU2015249649B2 (en) 2018-10-04
WO2015164588A1 (fr) 2015-10-29
PH12016502079B1 (en) 2016-12-19
PT3134430T (pt) 2018-04-20
DOP2016000284A (es) 2017-02-15
AU2018271369A1 (en) 2018-12-20
BR112016024515B1 (pt) 2020-03-31
RU2016145608A3 (fr) 2018-12-26
AU2015249649A1 (en) 2016-11-10
SG11201608767XA (en) 2016-11-29
PE20170299A1 (es) 2017-05-06
UY36095A (es) 2015-10-30
JP2019162114A (ja) 2019-09-26
TW202024123A (zh) 2020-07-01
ES2672368T3 (es) 2018-06-14
RU2016145608A (ru) 2018-05-28
AR100168A1 (es) 2016-09-14
EP3134430A1 (fr) 2017-03-01
RU2699285C2 (ru) 2019-09-04
TW201620928A (zh) 2016-06-16
US20250145688A1 (en) 2025-05-08
AU2020202247A1 (en) 2020-04-23
IL272612A (en) 2020-03-31
CL2016002683A1 (es) 2017-07-07
PL3134430T3 (pl) 2018-08-31
US20210040178A1 (en) 2021-02-11
KR102079919B1 (ko) 2020-02-24
MX2019013587A (es) 2020-01-13
MY181986A (en) 2021-01-18
UA118286C2 (uk) 2018-12-26
CN106459221B (zh) 2020-09-01
RS57153B1 (sr) 2018-07-31
NZ725476A (en) 2023-09-29
JP6523331B2 (ja) 2019-05-29
DK3134430T3 (en) 2018-05-22
CA2946402A1 (fr) 2015-10-29
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
US20240174731A1 (en) 2024-05-30
JP2017513503A (ja) 2017-06-01
HUE038914T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
EP3679071A4 (fr) Protéines de liaison à nkg2d, cd16 et un antigène associé à une tumeur
PH12016501644A1 (en) Binding proteins and methods of use thereof
SG10201707267RA (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
EA202091567A1 (ru) Химерные белки мти
WO2016007919A3 (fr) Fragments d'anticorps pour détecter un cancer et méthodes d'utilisation
EP3778644A3 (fr) Protéines de fusion fgfr-tacc et procédés associés
EP3227681A4 (fr) Anticorps anti-acétaminophène et produits d'addition acétaminophène-protéine
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
NZ761611A (en) Single-chain trail-receptor agonist proteins
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей